We postulated that the dichotomy in response to CTLA4 blockade could be leveraged for increasing treatment efficacy, by visualizing the immunotherapy-induced response in the regressing tumour as a complex, modular network of interacting gene products7, 8. Here, CTLA4 is linked to neoplasm.